Ocugen Inc (NASDAQ:OCGN) — Market Cap & Net Worth
Market Cap & Net Worth: Ocugen Inc (OCGN)
Ocugen Inc (NASDAQ:OCGN) has a market capitalization of $461.52 Million ($461.52 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12941 globally and #3003 in its home market, demonstrating a 7.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ocugen Inc's stock price $1.80 by its total outstanding shares 327320112 (327.32 Million). Analyse Ocugen Inc cash conversion from operations to see how efficiently the company converts income to cash.
Ocugen Inc Market Cap History: 2015 to 2026
Ocugen Inc's market capitalization history from 2015 to 2026. Data shows change from $68.74 Billion to $589.18 Million (-37.81% CAGR).
Index Memberships
Ocugen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #332 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1235 of 3165 |
Weight: Ocugen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ocugen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ocugen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
64.98x
Ocugen Inc's market cap is 64.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $170.21 Million | $42.62K | -$20.24 Million | 3993.58x | N/A |
| 2020 | $599.00 Million | $43.00K | -$21.82 Million | 13930.13x | N/A |
| 2021 | $1.49 Billion | $22.92K | -$58.37 Million | 64978.47x | N/A |
| 2022 | $425.52 Million | $2.49 Million | -$77.83 Million | 171.03x | N/A |
| 2023 | $188.21 Million | $6.04 Million | -$63.08 Million | 31.18x | N/A |
| 2024 | $263.49 Million | $4.05 Million | -$54.05 Million | 64.98x | N/A |
Competitor Companies of OCGN by Market Capitalization
Companies near Ocugen Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Ocugen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Ocugen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ocugen Inc's market cap moved from $68.74 Billion to $ 589.18 Million, with a yearly change of -37.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $589.18 Million | +33.33% |
| 2025 | $441.88 Million | +67.70% |
| 2024 | $263.49 Million | +40.00% |
| 2023 | $188.21 Million | -55.77% |
| 2022 | $425.52 Million | -71.43% |
| 2021 | $1.49 Billion | +148.63% |
| 2020 | $599.00 Million | +251.92% |
| 2019 | $170.21 Million | -90.15% |
| 2018 | $1.73 Billion | -95.71% |
| 2017 | $40.26 Billion | +22.75% |
| 2016 | $32.80 Billion | -52.29% |
| 2015 | $68.74 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Ocugen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $461.52 Million USD |
| MoneyControl | $461.52 Million USD |
| MarketWatch | $461.52 Million USD |
| marketcap.company | $461.52 Million USD |
| Reuters | $461.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more